Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,959,330
  • Shares Outstanding, K 281,109
  • Annual Sales, $ 44,580 K
  • Annual Income, $ -328,070 K
  • EBIT $ -395 M
  • EBITDA $ -371 M
  • 60-Month Beta 0.81
  • Price/Sales 43.01
  • Price/Cash Flow N/A
  • Price/Book 3.28

Options Overview Details

View History
  • Implied Volatility 81.30% ( -3.36%)
  • Historical Volatility 58.72%
  • IV Percentile 37%
  • IV Rank 19.72%
  • IV High 135.52% on 02/27/24
  • IV Low 67.98% on 09/24/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 4,334
  • Volume Avg (30-Day) 4,414
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 135,103
  • Open Int (30-Day) 120,657

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.39
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.48
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +2.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.95 +17.31%
on 10/10/24
7.10 -1.69%
on 10/17/24
+0.80 (+12.94%)
since 10/07/24
3-Month
5.89 +18.61%
on 09/04/24
8.16 -14.51%
on 08/26/24
+0.61 (+9.58%)
since 08/07/24
52-Week
5.03 +38.63%
on 11/10/23
15.74 -55.65%
on 02/27/24
+0.87 (+14.24%)
since 11/07/23

Most Recent Stories

More News
Recursion Pharmaceuticals: Q3 Earnings Snapshot

Recursion Pharmaceuticals: Q3 Earnings Snapshot

RXRX : 7.03 (+0.86%)
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

RXRX : 7.03 (+0.86%)
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

In an environment where the typical small biotech name is riskier than not, this one is curiously different.

RXRX : 7.03 (+0.86%)
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

RXRX : 7.03 (+0.86%)
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

This company stands to benefit from a shifting pharmaceutical industry landscape.

RXRX : 7.03 (+0.86%)
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

RXRX : 7.03 (+0.86%)
Prediction: These 2 Stocks Could Soar in 2025

The key word here is "could."

BIOA : 21.97 (-4.23%)
RXRX : 7.03 (+0.86%)
Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Wood has a stake in this stock, but it's hardly an "all-in" bet.

RXRX : 7.03 (+0.86%)
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.

RXRX : 7.03 (+0.86%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite falling stocks.

BLDE : 3.80 (+1.60%)
DDD : 3.47 (-2.80%)
RXRX : 7.03 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 7.37
2nd Resistance Point 7.21
1st Resistance Point 7.09
Last Price 7.03
1st Support Level 6.81
2nd Support Level 6.65
3rd Support Level 6.53

See More

52-Week High 15.74
Fibonacci 61.8% 11.65
Fibonacci 50% 10.39
Fibonacci 38.2% 9.12
Last Price 7.03
52-Week Low 5.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar